Skip to Main Content

Paper Details

The CDK4/6 inhibitors biomarker landscape: The most relevant biomarkers of response or resistance for further research and potential clinical utility.
Crit Rev Oncol Hematol
1
2023
Author NameAffiliation
Giuseppe CuriglianoUniversity of Milan, European Institute of Oncology, IRCCS
Carmen CriscitielloUniversity of Milan, European Institute of Oncology, IRCCS
  • 1 - 2

Datasets

Release 1.2